Emmaus Life Sciences Inc (EMMA)

OTC Markets
Currency in USD
0.03
0.00(0.00%)
Closed
EMMA Scorecard
Full Analysis
Operates with a significant debt burden
Earnings results expected in 13 days
Fair Value
Day's Range
0.030.03
52 wk Range
0.010.13
Key Statistics
Edit
Prev. Close
0.03
Open
0.03
Day's Range
0.03-0.03
52 wk Range
0.01-0.13
Volume
20.58K
Average Volume (3m)
59.27K
1-Year Change
-75%
Book Value / Share
-0.84
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
EMMA Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year
Show more

Emmaus Life Sciences Inc Company Profile

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company’s lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Its pipeline products include ELS001/ELS007, a pharmaceutical grade L-glutamine, which has completed phase 3 clinical trial to treat sickle cell disease; ELS004, a pharmaceutical grade L-glutamine which has completed phase 1 clinical study to treat diverticulosis; ELS005 in preclinical study for the use and combination of KM10544 to treat blood cancers; ELS003, a lab device/research tool in preclinical study to measure transmittance of cell sheet; and ELS002, a chondrocyte cell sheet technology to replace knee cartilage replacement or to treat osteoarthritis is in preclinical study. It has a license agreement with Kainos Medicine, Inc., which includes the patent rights of IRAK4 inhibitor (KM10544) for the treatment of cancers. The company was founded in 2000 and is headquartered in Torrance, California.

Compare EMMA to Peers and Sector

Metrics to compare
EMMA
Peers
Sector
Relationship
P/E Ratio
−0.5x−2.2x−0.5x
PEG Ratio
−0.01−0.030.00
Price/Book
0.0x0.8x2.6x
Price / LTM Sales
0.1x6.0x3.0x
Upside (Analyst Target)
-28.2%56.3%
Fair Value Upside
Unlock23.5%10.0%Unlock

Earnings

Latest Release
Nov 19, 2024
EPS / Forecast
-- / 0.01
Revenue / Forecast
-- / 5.00M
EPS Revisions
Last 90 days

FAQ

What Is the Emmaus Life Sciences (EMMA) Stock Price Today?

The Emmaus Life Sciences stock price today is 0.03

What Stock Exchange Does Emmaus Life Sciences Trade On?

Emmaus Life Sciences is listed and trades on the OTC Markets stock exchange.

What Is the Stock Symbol for Emmaus Life Sciences?

The stock symbol for Emmaus Life Sciences is "EMMA."

What Is the Emmaus Life Sciences Market Cap?

As of today, Emmaus Life Sciences market cap is 1.75M.

What is Emmaus Life Sciences Earnings Per Share?

The Emmaus Life Sciences EPS is -0.057.

What Is the Next Emmaus Life Sciences Earnings Date?

Emmaus Life Sciences will release its next earnings report on 27 Mar 2025.

From a Technical Analysis Perspective, Is EMMA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.